ADMINISTRATIVE CORE Principal Investigator Matthew M. LaVail, Ph.D. is an internationally known senior vision scientist who has used many different types of research approaches, including anatomical, biochemical, classical genetic, molecular genetic and electrophysiological methods, as well as animal model development and neurotrophic factor and gene therapy studies for retinal degenerative diseases. His discoveries of circadian rod outer- segment disk shedding and the pharmaceutical rescue of degenerating photoreceptors have led to the establishment of new fields of vision research. He is highly respected at UCSF and in the vision research community. Dr. LaVail has been funded continuously by the NEI for the past 35 or more years with 6 different co-operative agreements, contracts and long-running research grants, so he is fully aware of both the research needs and regulations involved with NIH grants. Also, he has been an active member of the Core Grant Core Directors' Advisory Committee (see below), serving as the Imaging Core's first Director beginning in 1998. Through his leadership and effort in designing and constructing the Core, the Imaging Core has been the most heavily used of our Cores. Dr. LaVail distinguished himself, as well, in establishing procedures that would assure equitable access to the Core, even with very high usage at several times during the year just prior to several research meetings. One year before the retirement of the former Principal Investigator, Dr. Steven Kramer, Dr. LaVail was approved by the NE I to become the new Principal Investigator of the Core Grant effective July 1, 2002. We will use this process in case a Core Director or PI moves, retires or becomes unable to carry out the duties of the position, in which case the person will be identified by the Advisory Committee (see below), and the name will be submitted to the NEI for approval.

Agency
National Institute of Health (NIH)
Institute
National Eye Institute (NEI)
Type
Center Core Grants (P30)
Project #
5P30EY002162-37
Application #
8895935
Study Section
Special Emphasis Panel (ZEY1)
Project Start
Project End
Budget Start
2015-07-01
Budget End
2016-06-30
Support Year
37
Fiscal Year
2015
Total Cost
Indirect Cost
Name
University of California San Francisco
Department
Type
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94118
Choquet, Hélène; Paylakhi, Seyyedhassan; Kneeland, Stephen C et al. (2018) A multiethnic genome-wide association study of primary open-angle glaucoma identifies novel risk loci. Nat Commun 9:2278
Kelley, Kevin W; Ben Haim, Lucile; Schirmer, Lucas et al. (2018) Kir4.1-Dependent Astrocyte-Fast Motor Neuron Interactions Are Required for Peak Strength. Neuron 98:306-319.e7
González, Marta Mora; Solano, Marissé Masís; Porco, Travis C et al. (2018) Epidemiology of uveitis in a US population-based study. J Ophthalmic Inflamm Infect 8:6
Paylakhi, Seyyedhassan; Labelle-Dumais, Cassandre; Tolman, Nicholas G et al. (2018) Müller glia-derived PRSS56 is required to sustain ocular axial growth and prevent refractive error. PLoS Genet 14:e1007244
Lien, Anthony D; Scanziani, Massimo (2018) Cortical direction selectivity emerges at convergence of thalamic synapses. Nature 558:80-86
Resulaj, Arbora; Ruediger, Sarah; Olsen, Shawn R et al. (2018) First spikes in visual cortex enable perceptual discrimination. Elife 7:
Biswas, Pooja; Naeem, Muhammad Asif; Ali, Muhammad Hassaan et al. (2018) Whole-Exome Sequencing Identifies Novel Variants that Co-segregates with Autosomal Recessive Retinal Degeneration in a Pakistani Pedigree. Adv Exp Med Biol 1074:219-228
Stryker, Michael P; Löwel, Siegrid (2018) Amblyopia: New molecular/pharmacological and environmental approaches. Vis Neurosci 35:E018
Nachury, Maxence V (2018) The molecular machines that traffic signaling receptors into and out of cilia. Curr Opin Cell Biol 51:124-131
Kim, Jean; Kudisch, Max; da Silva, Nina Rosa Konichi et al. (2018) Long-term intraocular pressure reduction with intracameral polycaprolactone glaucoma devices that deliver a novel anti-glaucoma agent. J Control Release 269:45-51

Showing the most recent 10 out of 581 publications